Curis to Present at the Cantor Fitzgerald Global Healthcare Conference
September 22 2017 - 11:54AM
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the
development and commercialization of innovative and effective
therapeutics for the treatment of cancer, today announced that Ali
Fattaey, Ph.D., President and Chief Executive Officer, will present
at the Cantor Fitzgerald Global Healthcare Conference on Monday,
Sept. 25, 2017, at 3:35 p.m. EDT in New York.
A corresponding webcast of the presentation can be accessed by
visiting: http://wsw.com/webcast/cantor6/cris.
The webcast will be archived shortly after the live event and
available for 90 days following the conference, and also available
on the Investor Relations section of the Curis website at
www.curis.com.
About Curis
Curis is a biotechnology company focused on the development and
commercialization of innovative and effective drug candidates for
the treatment of human cancers, including its lead development
candidate, CUDC-907 which is being investigated in clinical studies
in patients with lymphomas and solid tumors. Curis is also engaged
in a broad collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of the PD1 and VISTA pathways, including PDL1/VISTA
antagonist CA-170, and oral small molecule antagonists of the PD1
and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well
as to molecules designed to inhibit the IRAK4 kinase, including
CA-4948. CA-170 is currently undergoing testing in a Phase 1
trial in patients with advanced solid tumors and lymphomas. Curis
is also party to a collaboration with Genentech, a member of the
Roche Group, under which Genentech and Roche are commercializing
Erivedge® for the treatment of advanced basal cell carcinoma, and
are further developing Erivedge in other diseases including
idiopathic pulmonary fibrosis and myelofibrosis. For more
information, visit Curis's website at www.curis.com.
For More Information:James E. Dentzer Chief
Financial Officer & Chief Administrative OfficerCuris, Inc.
617-503-6500 jdentzer@curis.com
Media ContactDavid SchullRusso Partners(212)
845-4271david.schull@russopartnersllc.com
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Apr 2023 to Apr 2024